Evidence map›Paper›PMID 35013710›Full record

ArticleBioMed research international2022

Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.

Hossein Mazaherpour, Masoomeh Sofian, Elham Farahani, Alireza Abdi, Sakine Mazaherpour, Anahita Bavand, Amitis Ramezani

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Hossein MazaherpourArak University of Medical Sciences, Arak, Iran.ORCID https://orcid.org/0000-0001-8609-0702
Masoomeh SofianInfectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran.ORCID https://orcid.org/0000-0002-8564-3659
Elham FarahaniArak University of Medical Sciences, Arak, Iran.ORCID https://orcid.org/0000-0002-7904-8247
Alireza AbdiKermanshah University of Medical Sciences, Kermanshah, Iran.ORCID https://orcid.org/0000-0002-3184-2564
Sakine MazaherpourTreatment Management of Social Security Organization of Khuzestan Province, Mahshahr, Iran.ORCID https://orcid.org/0000-0002-6963-0217
Anahita BavandClinical Research Department, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0002-1894-6764
Amitis RamezaniClinical Research Department, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0001-7233-5828
Arak University of Medical Sciences · IRPasteur Institute of Iran · IRIslamic Azad University Mahshahr · IRKermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several therapeutic regimens for COVID-19 have been studied, such as combination antiviral therapies. We aimed to compare outcome of two types of combination therapies atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r) plus hydroxychloroquine among COVID-19 patients. 108 patients with moderate and severe forms of COVID-19 were divided into two groups (each group 54 patients). One group received ATV/r plus hydroxychloroquine, and the other group received hydroxychloroquine plus LPV/r. Then, both groups were evaluated and compared for clinical symptoms, recovery rates, and complications of treatment regimens. Our findings showed a significant increase in bilirubin in ATV/r-receiving group compared to LPV/r receivers. There was also a significant increase in arrhythmias in the LPV/r group compared to the ATV/r group during treatment. Other findings including length of hospital stay, outcome, and treatment complications were not statistically significant. There is no significant difference between protease inhibitor drugs including ATV/r and LPV/r in the treatment of COVID-19 regarding clinical outcomes. However, some side effects such as hyperbilirubinemia and arrhythmia were significantly different by application of atazanavir or lopinavir.

Indexed as

COVID-19 Drug TreatmentAgedAntiviral AgentsArrhythmias, CardiacAtazanavir SulfateBilirubinCOVID-19Drug CombinationsDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineLength of StayLopinavirMaleAntiviral Agentsatazanavir, ritonavir drug combinationAtazanavir SulfateBilirubinDrug CombinationsHydroxychloroquineLopinavirlopinavir-ritonavir drug combinationRitonavir

Identifiers

PMID35013710
PMCPMC8742149
OpenAlexW4205286483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.